Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Liraglutide 3.0 mg in Obesity
NCT03523273Phase 2Completed
- Start
- Nov 2017
- Primary completion
- Aug 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing Liraglutide with Placebo (2 arms). Primary endpoint: Gastric Emptying of Solids (T1/2) at 16 weeks. Started Nov 2017; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03523273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03523273.